Does Retatrutide Need Carbs to Work? The Truth About Reta and Low Carb

Retatrutide is a triple agonist, meaning it activates three different receptors in the body, and one of those receptors responds to glucagon, which is the hormone that tends to get people confused when they start asking whether this drug can work on a low carb diet. The short answer is that it can, and understanding why requires a closer look at what glucagon actually does and what the research says about how the body handles fat and fuel when carbohydrates are low.

Glucagon is a hormone produced by the pancreas and it plays a major role in regulating blood sugar, so when people hear that retatrutide activates glucagon receptors they sometimes assume the drug must depend on carbohydrates to function. Glucagon does bind to receptors in the liver, it does stimulate a process called gluconeogenesis where the body converts amino acids and glycerol into glucose, and it does promote lipolysis which is the release of fatty acids from stored body fat to be used as fuel. All of that is accurate and well established in the biochemical literature.

The confusion comes in when that information gets used to conclude that retatrutide needs carbohydrates to work properly, because the mechanisms responsible for fat loss on this drug do not actually depend on carbohydrate availability. Retatrutide drives fat loss through hepatic fatty acid oxidation, through lipolysis, and through increases in resting energy expenditure, and none of those pathways require glucose or dietary carbs to function. They run on stored body fat, which is exactly what the drug is designed to target.

The gluconeogenesis piece is worth unpacking because it is where the argument about needing carbs tends to originate. When glucagon signals the liver to produce glucose, the liver does have a preferred method for doing that, which is called glycogenolysis, meaning it breaks down glycogen that is already stored and releases glucose from that. Glycogen is essentially the storage form of carbohydrates in the body, so when someone is eating plenty of carbs the liver has a ready supply of glycogen to pull from. The concern is that on a low carb diet that glycogen supply is reduced or depleted, and some people assume this means glucagon signaling becomes less effective or that the drug loses its potency.

But the body does not simply shut down when glycogen is low, and this is a critical point. When glycogen stores are depleted the liver shifts to gluconeogenesis and starts making glucose from other substrates like amino acids and glycerol, and this is a normal adaptive response that humans have relied on throughout history during periods of low carbohydrate availability. The body is built to handle this situation and the liver continues to manage blood glucose through these alternative pathways so that essential tissues like the brain continue to receive fuel.

Low carb diets actually tend to raise glucagon levels naturally, and this happens because lower carbohydrate intake means lower insulin levels and the ratio between glucagon and insulin shifts in favor of glucagon. So instead of retatrutide working against someone on a low carb diet, the glucagon component of the drug may actually align well with the metabolic state that low carb eating produces. The two are more likely synergistic than they are at odds with each other.

There is one legitimate safety consideration that does arise when combining retatrutide with low carb eating and it involves ketoacidosis, which is a condition where ketones build up in the blood to a dangerous level and lower the blood pH. Retatrutide increases the production of ketones, and the Phase 3 clinical trials resulted in a ketoacidosis warning being added to the drug's profile because of this. This is not something to dismiss, but it is also not something that applies equally to every person using the drug.

The ketoacidosis risk is most relevant in a specific combination of circumstances, and those include someone following a very strict ketogenic diet, using a high dose of retatrutide, and experiencing an additional stressor like illness or dehydration. The risk is also elevated in people with type 2 diabetes and in people using a class of diabetes medications called SGLT2 inhibitors, which themselves carry a known risk of ketoacidosis. For someone who is eating a moderate low carb diet in the range of 50 to 100 grams of carbohydrates per day, is not diabetic, and is not on SGLT2 inhibitors, this risk is considerably lower and may not be a meaningful clinical concern.

Understanding the difference between a theoretical mechanism and an actual clinical risk is important when evaluating claims about peptides and metabolic drugs, so the fact that glucagon stimulates gluconeogenesis does not automatically mean a drug built around glucagon activation requires carbs to work. The body is metabolically flexible and it adapts to fuel availability, and the fat burning pathways that retatrutide activates are not gated by how many carbohydrates someone is consuming on a given day.

Research into GLP-1 based drugs has consistently shown that increases in basal energy expenditure and reductions in fat mass occur across different dietary contexts, and the mechanisms responsible for those outcomes involve fatty acid oxidation and thermogenesis rather than carbohydrate metabolism specifically. Studies looking at similar agonists have found meaningful reductions in body weight and fat tissue even in conditions where carbohydrate intake is not a focus of the intervention.

So the takeaway is that retatrutide does not need carbohydrates to work, and the fat loss mechanisms it activates function regardless of whether someone is eating a standard diet or following a low carb approach. The glucagon receptor activity in the drug does involve glucose metabolism but that does not create a dependence on dietary carbs because the liver has multiple tools for managing glucose production and the primary fat burning pathways operate on stored fat rather than ingested carbohydrates. The one area where carb intake does matter is in managing the ketoacidosis risk, and that conversation is most important for people in the higher risk categories rather than for the general person eating moderate amounts of carbohydrates.

---

References

1. Gusenbauer M, Haddaway NR. Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. Res Synth Methods. 2020. Source
2. Lindsey WT, Olin BR. PubMed searches: overview and strategies for clinicians. Nutr Clin Pract. 2013. Source
3. Pirani C, Camilleri J. Effectiveness of root canal filling materials and techniques for treatment of apical periodontitis: A systematic review. Int Endod J. 2023. Source
4. Sonagra AD, Zubair M, Motiani A. Hexokinase Method. . 2026. Source
5. Ross BD, Hems R, Freedland RA et al.. Carbohydrate metabolism of the perfused rat liver. Biochem J. 1967. Source
6. Feinman RD, Makowske M. Metabolic syndrome and low-carbohydrate ketogenic diets in the medical school biochemistry curriculum. Metab Syndr Relat Disord. 2003. Source
7. Rossetti CL, Andrade IS, Fonte Boa LF et al.. Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats. Mol Cell Endocrinol. 2024. Source
8. Gao H, Zhao Q, Li K et al.. EGLP-1 lowers body weight better than exendin-4 by reducing food intake and increasing basal energy expenditure in diet-induced obese mice. Exp Cell Res. 2021. Source
9. Tomas E, Stanojevic V, McManus K et al.. GLP-132-36amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice. Diabetes. 2015. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness